. 2020 May 15:1–9. doi: 10.1080/07391102.2020.1764392
© 2020 Informa UK Limited, trading as Taylor & Francis
Group
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
Figure 4.
Covalent docking analysis of ritonavir inside the SARS-CoV-2 Mpro.